Perceptive Advisors

Exagen Inc. is a commercial-stage diagnostics company focused on developing and commercializing innovative testing products for autoimmune and autoimmune-related diseases. Headquartered in Vista, California, Exagen utilizes its proprietary Cell-Bound Complement Activation Products technology to enhance diagnostic care for conditions like systemic lupus erythematosus and rheumatoid arthritis. The company offers a diverse portfolio of testing products under its AVISE brand, including AVISE CTD for differential diagnosis of connective tissue diseases, AVISE Lupus for monitoring complement system activation, and multiple panels for assessing various autoimmune markers. These products facilitate timely diagnosis and effective therapeutic interventions, enabling rheumatologists to improve patient care. Since its founding in 2002, Exagen has remained committed to addressing the needs of patients suffering from chronic autoimmune diseases.

Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.

Orpyx Medical Technologies Inc. is a Calgary-based company that develops innovative mobility sensor devices aimed at supporting diabetic patients in maintaining their mobility. Founded in 2010, the company offers several key products, including the Orpyx SI sensory insoles, which are designed to manage and prevent diabetic foot ulcers and limb loss by capturing real-time data related to pressure, temperature, and movement. Additionally, Orpyx provides Kinetyx, a mobile in-shoe pressure management system that collects clinical plantar pressure data for various applications, including sports medicine and therapeutic use. Another notable product is SurroGait Rx, which assists multiple sclerosis patients in improving their mobility and balance. Orpyx Medical Technologies emphasizes the importance of prevention in healthcare and collaborates with global stakeholders to promote sustainable health solutions.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.

Biodesix is a data-driven diagnostic solutions company focused on lung disease. It provides blood-based tests across the lung cancer continuum to aid risk assessment, diagnosis, monitoring and treatment guidance. Key tests include Nodify XL2 and Nodify CDT for reclassifying malignancy risk in suspicious lung nodules, along with VeriStrat immune profiling and GeneStrat tumor profiling to support treatment decisions. The company operates a CLIA-certified laboratory and delivers results in under 72 hours. Biodesix also develops and commercializes multivariate protein diagnostics based on its proprietary mass spectrometry platform, and partners with biopharmaceutical companies to create companion diagnostics and support diagnostic research, clinical trial testing, and development and commercialization of diagnostics. In addition to in-house testing services, it provides contract services to biopharma clients across discovery, development and testing phases. Biodesix is headquartered in Boulder, Colorado.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Twin Health, Inc. is a precision health company that focuses on reversing diabetes and chronic diseases through its innovative health platform. Founded in 2018 and based in Mountain View, California, with additional offices in Chennai and Bengaluru, India, the company utilizes artificial intelligence and Internet-of-Things technologies to assess and restore metabolic health. Its platform analyzes complex biosignals from wearable sensors to predict metabolic outcomes and provide tailored treatment recommendations based on individual metabolic profiles. Twin Health has developed unique technology, with several patents granted and pending, that underpins its mission to normalize blood sugar levels and reduce reliance on medications.

HilleVax is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HilleVax is dedicated to addressing significant public health challenges through its vaccine initiatives.

Founded in 1999, SomaLogic specializes in the discovery, development, and commercialization of life science research tools and clinical diagnostic products centered around its proprietary SOMAmer/SOMAscan technology. This platform enables protein measurement at scale, facilitating biomarker discovery for various diseases, drug development, and clinical diagnostics.

GeneDx specializes in delivering personalized insights from genomic data to improve health outcomes. It combines extensive genetic expertise with advanced data science capabilities.

Point Biopharma Global Inc., established in 2019 and headquartered in Toronto, Canada, specializes in the development and commercialization of radioligand therapies for cancer treatment. The company's portfolio comprises several assets, including PNT2002, PNT2004, PNT2003, and PNT2001. Point Biopharma leverages its expertise in radioisotopes like Actinium-225 and Lutetium-177, along with advanced manufacturing technology and a patient-centric approach, to revolutionize theragnostic drug development and radioligand commercialization on a global scale.

Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Juno Diagnostics is a San Diego-based health technology company developing noninvasive, cell-free DNA-based prenatal testing and other genetic testing tools. The company focuses on creating simple, cost-effective devices to enable point-of-need and in-home genetic testing, reducing the cost, lead times, and need for phlebotomy associated with traditional testing. Its work spans applications in fetal screening, epigenetics, inherited diseases, and cancer diagnostics, aiming to democratize access to high-value genetic information for patients and physicians.

Renovia Inc., founded in 2016 and based in Boston, Massachusetts, was a healthcare company focused on developing prescription digital therapeutics for pelvic floor disorders. The company's innovative device provided a clinically validated treatment for conditions such as stress, mixed, and urgent urinary incontinence, including overactive bladder. This technology allowed for real-time visualization of pelvic movement during muscle training sessions, facilitating a non-surgical and drug-free approach to treatment. However, Renovia ceased operations in late 2022 following a strategic review by its investors, and in January 2023, the majority of its assets, including intellectual property, were acquired by Axena Health, Inc.

Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.

Prometheus Biosciences, established in 1995 and headquartered in San Diego, California, specializes in developing and commercializing innovative pharmaceutical and diagnostic products. The company's portfolio includes tests that enable physicians to provide personalized patient care, such as monitoring drug and anti-drug antibody levels, diagnosing and prognosticating inflammatory bowel disease (IBD), and detecting celiac disease and lactose intolerance. Prometheus also offers therapeutic products like Entocort EC for treating Crohn's disease and has agreements to develop and market other drugs. The company's commitment to innovation positions it as a leader in precision healthcare, particularly in gastroenterology.

Metabolon develops metabolomics-based platforms and clinical diagnostic tests for early disease detection and precision medicine. It offers blood tests like QUANTOSE IR and QUANTOSE IGT, and Meta IMD for inherited metabolic disorders. The company serves various sectors including academia, biotech/pharmaceuticals, and precision medicine. It has strategic partnerships with major pharmaceutical companies and other industries.

Metabolon develops metabolomics-based platforms and clinical diagnostic tests for early disease detection and precision medicine. It offers blood tests like QUANTOSE IR and QUANTOSE IGT, and Meta IMD for inherited metabolic disorders. The company serves various sectors including academia, biotech/pharmaceuticals, and precision medicine. It has strategic partnerships with major pharmaceutical companies and other industries.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

Thrive Earlier Detection is a healthcare company dedicated to saving lives through early detection of cancer. It develops CancerSEEK, a liquid biopsy test designed to identify various cancers in their earliest stages via blood analysis.

Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company based in Emeryville, California, focused on developing innovative gene therapies for unmet medical needs. The company utilizes targeted and evolved adeno-associated virus (AAV) vectors to create its product candidates, which are concentrated in the therapeutic areas of ophthalmology, cardiology, and pulmonology. Key candidates in its portfolio include 4D-125, currently in a Phase I/II trial for X-linked retinitis pigmentosa, and 4D-110, undergoing Phase I trials for choroideremia. Additionally, 4D-310 is in Phase I/II trials for Fabry disease, while investigational drugs 4D-150 and 4D-710 are being developed for wet age-related macular degeneration and cystic fibrosis lung disease, respectively. Founded in 2013, 4D Molecular Therapeutics aims to advance its gene therapies to address significant health challenges.

DNAnexus, Inc. is a cloud-based provider of genome informatics and data management tools, primarily serving enterprises and organizations involved in genomic medicine. Founded in 2009 and headquartered in Mountain View, California, the company offers a platform that facilitates the analysis of raw sequencing data and the integration of genomic data with clinical information. Its suite of products includes MOSAIC Microbiome for collaborative research on the human microbiome, DNAnexus Apollo for clinico-genomic data exploration, and DNAnexus Titan for data analysis. Additionally, the DNAnexus Portals provide secure online workspaces for cross-disciplinary collaboration, while the Clinico-Genomic Data Solution addresses the need for disease-specific datasets through partnerships with healthcare providers. The company has established itself as a key player in the biopharmaceutical, diagnostic, and academic research sectors, enabling clients to tackle complex challenges in human health with enhanced security and scalability. DNAnexus also maintains a strategic alliance with WuXi NextCODE Genomics and has locations in San Francisco, London, and Prague.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

AgaMatrix, Inc. is a company focused on developing and manufacturing advanced biosensors and blood glucose monitoring systems for individuals with diabetes. Established in 2001 and headquartered in Salem, New Hampshire, AgaMatrix offers an array of products designed to enhance diabetes care, including mobile blood glucose meters and data management software. One of its key innovations is the WaveSense technology, which personalizes testing by improving accuracy and correcting for potential errors arising from variations in blood samples and environmental conditions. The company also provides the AgaMatrix Diabetes Manager, which consolidates tracking of glucose, insulin, carbohydrates, and weight, as well as the Zero-Click system for streamlined data management. With a strong portfolio of over 160 patents covering its technologies, AgaMatrix partners with notable firms such as Biocorp Production and Sanofi to distribute its products through retail channels.

Kindbody is a comprehensive fertility clinic network and family-building benefits provider that offers a wide range of services aimed at improving access to healthcare for women. The company provides both virtual and in-person care, including fertility assessments, education, preservation, genetic testing, in vitro fertilization (IVF), donor and surrogacy services, and adoption. By partnering with employers, Kindbody delivers financial, medical, and emotional support to employees pursuing parenthood. The company serves more than 100 employers, covering over 2.4 million lives, while also providing direct fertility care through its network of signature clinics, mobile clinics, and partner clinics across the country. With a focus on affordability and accessibility, Kindbody employs modern technology to deliver holistic health and fertility services.

Lyra Therapeutics is a clinical-stage therapeutics company focused on the development and commercialization of localized treatments for ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to affected tissue for sustained effect with a single administration. The company’s initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices intended for in-office administration to provide up to six months of continuous therapy to the sinonasal passages for chronic rhinosinusitis, with mometasone furoate as the active ingredient. Founded in 2005 and headquartered in Watertown, Massachusetts.

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company based in Emeryville, California, focused on developing innovative gene therapies for unmet medical needs. The company utilizes targeted and evolved adeno-associated virus (AAV) vectors to create its product candidates, which are concentrated in the therapeutic areas of ophthalmology, cardiology, and pulmonology. Key candidates in its portfolio include 4D-125, currently in a Phase I/II trial for X-linked retinitis pigmentosa, and 4D-110, undergoing Phase I trials for choroideremia. Additionally, 4D-310 is in Phase I/II trials for Fabry disease, while investigational drugs 4D-150 and 4D-710 are being developed for wet age-related macular degeneration and cystic fibrosis lung disease, respectively. Founded in 2013, 4D Molecular Therapeutics aims to advance its gene therapies to address significant health challenges.

Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.

Renovia Inc., founded in 2016 and based in Boston, Massachusetts, was a healthcare company focused on developing prescription digital therapeutics for pelvic floor disorders. The company's innovative device provided a clinically validated treatment for conditions such as stress, mixed, and urgent urinary incontinence, including overactive bladder. This technology allowed for real-time visualization of pelvic movement during muscle training sessions, facilitating a non-surgical and drug-free approach to treatment. However, Renovia ceased operations in late 2022 following a strategic review by its investors, and in January 2023, the majority of its assets, including intellectual property, were acquired by Axena Health, Inc.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, specializing in the discovery and development of antiviral drugs targeting respiratory syncytial virus (RSV). Founded in 2011, ReViral is focused on creating innovative first-in-class compounds, including a highly potent fusion inhibitor designed specifically for treating severe RSV infections, particularly in vulnerable populations such as neonates. By advancing these novel antiviral treatments, ReViral aims to address significant unmet medical needs and expand the antiviral market, ultimately improving patient outcomes for those affected by RSV.

IDEAYA Biosciences is an oncology-focused biotechnology company dedicated to discovering targeted therapeutics for patient populations selected using molecular diagnostics. Its pipeline includes small molecule inhibitors targeting DNA damage and repair pathways, such as MAT2A, PARG, and Pol-theta, as well as immuno-oncology therapies targeting the tumor microenvironment.

Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.

Singulex develops and commercializes single molecule counting technology for clinical diagnostics and scientific discovery. Its flagship product, the Sgx Clarity System, enables ultra-sensitive detection of biomarkers down to femtograms/mL, aiding in cardiovascular health management and personalized wellness programs. Singulex serves pharmaceutical R&D labs, clinical research organizations, and academic institutions worldwide.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

Motus GI Holdings, Inc. is a medical technology company based in Fort Lauderdale, Florida, with operations in the United States and Israel. The company specializes in developing endoscopy solutions aimed at improving clinical outcomes and reducing costs associated with gastrointestinal conditions. Its primary product, the Pure-Vu System, is designed to assist in the cleaning of poorly prepared colons during colonoscopy procedures, thereby enhancing the overall patient experience and aiding in the early detection of colorectal cancer and other gastrointestinal diseases. The Pure-Vu System has received clearance from the U.S. Food and Drug Administration and holds CE marking for use in the European Economic Area.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

VitalConnect is a company that specializes in wearable biosensor technology for wireless patient monitoring. It develops innovative solutions that enable continuous monitoring and recording of patients' vital signs through an adhesive patch applied to the body. The technology integrates expertise in biomedical engineering, data analytics, and chip design, allowing vital data to be displayed on mobile devices and computer systems. This capability empowers healthcare professionals to respond promptly to urgent situations and gain valuable insights into patient health, facilitating informed decision-making in both inpatient and outpatient settings, including hospital monitoring, post-discharge care, and cardiac monitoring.

Vapotherm, Inc. is a medical technology company specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat patients of all ages experiencing respiratory distress. Headquartered in Exeter, New Hampshire, the company offers a range of precision flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through a small-bore nasal interface. Vapotherm also provides various companion products, such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air, and aerosol solutions for medication delivery. Additionally, the company offers disposable products, including single-use nasal interfaces and Oxygen Assist Modules to help clinicians maintain target oxygen levels. Vapotherm generates revenue primarily through direct sales to hospitals in the United States and through distributors in select international markets. Founded in 1993, the company is committed to enhancing clinical outcomes and improving the quality of life for patients.

Outset Medical is a medical technology company that develops innovative hemodialysis systems. Founded in 2003, it specializes in the Tablo dialysis machine, designed for both acute and chronic settings. The Tablo system features integrated water purification, on-demand dialysate production, software connectivity capabilities, and sensor-based automation.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.